NEULAND LABORATORIES LTD.

Neuland Laboratories Ltd has announced a Board of Directors meeting scheduled for November 3, 2026. The primary agenda is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. These results will be both standalone and consolidated. Concurrently, the company has extended its trading window closure, which began on October 1, 2026, and will remain shut until 48 hours after the financial results are declared. This measure is in accordance with the company's Insider Trading Code.

Neuland Laboratories Ltd has announced that the US FDA has issued an Establishment Inspection Report (EIR) for its Unit 3 manufacturing facility located in Gaddapotharam Village, Sangareddy District. The inspection, which took place from August 10 to August 14, 2026, has been concluded by the US FDA as 'closed'. This development pertains to the inspection conducted at their facility.

Neuland Laboratories Ltd has announced the closure of its trading window for dealing in equity shares. This closure is in accordance with the company's Insider Trading Code and will be effective from October 1, 2026. The window will reopen 48 hours after the declaration of the financial results for the quarter and half-year ended September 30, 2026. The specific date for the Board Meeting to approve these financial results will be communicated separately.

Neuland Laboratories has announced the operational commencement of its first commercial peptide manufacturing module, significantly expanding its capacity. This module offers 7000L reactor capacity, including both solid-phase (SPPS) and liquid-phase (LPPS) synthesis capabilities, along with DAC columns and lyophilisers. The company is accelerating expansion due to rising customer demand, with foundational infrastructure for a second module already in place. Module two is planned for up to 18,000 L reactor capacity. This expansion supports growing peptide pipelines beyond obesity and metabolic diseases, with oncology emerging as a key area. Neuland's CEO highlighted the goal to meet demand for the next decade, supported by a team of 212 peptide experts. This follows a period of strong growth, with revenues up 116% in recent quarterly results.

Neuland Laboratories Ltd announced board approval for a capital expenditure of ₹126 crores to acquire approximately 134 acres of land in Kakinada, Andhra Pradesh. This strategic acquisition is intended for future expansion of the company's operations. The company also holds a right of first refusal for an additional 66 acres, potentially increasing the total land parcel to 200 acres. The investment will be financed through internal accruals.

Malabar India Fund Limited has disclosed the sale of 2,72,634 equity shares, representing 2.12% of the total share capital, in Neuland Laboratories Ltd. The sale occurred in the open market between August 10, 2024, and August 14, 2026. Following the transaction, Malabar India Fund's shareholding in Neuland Laboratories has reduced from 7.18% to 5.06%. The total equity share capital of Neuland Laboratories remains unchanged at ₹12,82,98,890, comprising 1,28,29,889 equity shares of ₹10 each.

Neuland Laboratories Ltd has announced the completion of a US FDA inspection at its Unit 3 manufacturing facility in Gaddapotharam village, Sangareddy District, which took place from August 10th to 14th, 2026. The inspection resulted in one observation from the US FDA, pertaining to procedural improvements in water and environmental monitoring. The company plans to submit its response to the US FDA within the stipulated timelines. This update is crucial for investors monitoring regulatory compliance and operational standards.

Neuland Laboratories Ltd announced the execution of a corporate guarantee of ₹40 crores in favor of Gland Pharma Limited. This guarantee is in connection with a Loan Licence Agreement to establish dedicated manufacturing capacity and incur capital expenditure for the manufacture of certain products. The company also approved its unaudited financial results for the quarter ended June 30, 2026, and a capacity expansion at its Unit 1 facility. The guarantee represents a contingent liability with no immediate impact on the company's financials. The capacity expansion involves an investment of ₹39.8 crores and is expected to be completed in 6-7 months.

Neuland Laboratories Ltd announced board approval for a significant manufacturing capacity expansion at its Unit 1 in Telangana. The company will add 18 KL to its existing capacity, requiring an investment of ₹39.8 crores (including GST). This expansion is slated for completion within 6-7 months and will be financed through internal accruals, aimed at catering to growing customer demand. Additionally, the board approved the execution of a corporate guarantee of ₹40 crores in favor of Gland Pharma Limited for a loan license agreement to establish dedicated manufacturing capacity. The company also disclosed its unaudited financial results for the quarter ended June 30, 2026.

Neuland Laboratories Limited announced its financial results for the quarter ended June 30, 2026. Total income for Q1 FY27 stood at ₹650.1 crore, a significant increase of 116.3% year-on-year from ₹300.6 crore in Q1 FY26. EBITDA surged by 448.2% to ₹231.1 crore from ₹42.1 crore in the prior year's quarter. Profit After Tax (PAT) also saw a substantial jump of 975.0% to ₹147.4 crore from ₹13.7 crore in Q1 FY26. The company's CEO highlighted encouraging performance from CMS & GDS businesses and strong customer conversations, with plans for increased investment based on available opportunities. An earnings call is scheduled for August 5, 2026.